BioNTech SE (B1NT34) Fair Value & Analysis
Healthcare · BR · Market cap R$116B
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 11 days ago
Share price +11.5% over the past month.
Price vs Fair Value (12 months)
12‑month range R$25.87 – R$37.89 · fair‑value band R$16.04 – R$26.73 · the R$29.46 price screens above the R$21.38 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BioNTech SE (B1NT34) currently trades at R$29.46, while our model-based Fair Value estimate is R$21.38 — implying the stock looks roughly 27.4% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, BioNTech SE generated revenue of R$2.8B at a net margin of -44.6%. Revenue declined 35.4% year over year. It earns a return on equity of -6.7%. Fundamentals as of Jun 24, 2026
Our scenario range runs from R$16.04 (bear case) to R$26.73 (bull case); at R$29.46, the current price sits above that range. The share trades about 28% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -38% fair-value upside — at -27%, B1NT34 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BioNTech SE reported revenue of R$2.9B in FY2025 versus R$19.0B in FY2021, a compound −37.6%/yr. Reported net income was −R$1.1B in FY2025.
Is B1NT34 fairly valued? → Check now
Recent news
- VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
- Is BioNTech SE (BNTX) A Good Stock To Buy Now?
- BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study
- Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth Signals
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $612.50 | $1,280 | +109% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BioNTech SE (B1NT34) undervalued?
What is the fair value of B1NT34?
What is the quality score of B1NT34?
What is the revenue of BioNTech SE (B1NT34)?
What is the net profit margin of B1NT34?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.